Plain Prescription Prices Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Plain Prescription Prices Act (H.R. 7970) was a bill introduced in the 118th Congress aimed at addressing issues related to prescription drug pricing. The bill was referred to the Subcommittee on Health but did not advance further and ultimately failed or expired. Specific details about the bill's provisions, mechanisms, or intended reforms are not available in the provided source data.
H.R. 7970 sought to impact prescription drug pricing but did not progress beyond early committee referral and expired without enactment.
- The bill was introduced in the House of Representatives during the 118th Congress.
- It was referred to the Subcommittee on Health on December 17, 2024.
- The bill did not advance past the subcommittee stage and is listed as failed or expired.
['Potential beneficiaries could include patients seeking more affordable prescription drugs, healthcare providers, and possibly health insurers, though specific beneficiaries cannot be confirmed due to lack of bill text.']
['Lack of available bill text limits understanding of implementation challenges or costs.', 'No information on enforcement mechanisms or funding sources is provided.', 'Oversight provisions and authority delegation remain unspecified.']
The bill was introduced during the 118th Congress and referred to the House Subcommittee on Health. It did not advance further and expired, indicating limited legislative momentum or prioritization within the congressional session. No summary or detailed legislative history is available to provide additional context.
High concern review — 3 hidden impact flags detected
GovScope reviewed 3 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced prescription drug pricing transparency or affordability, potentially affecting pharmaceutical markets and healthcare costs.', 'Failure to pass may maintain the status quo in prescription drug pricing policy.']
The absence of bill text and an official summary limits transparency and public understanding of the bill's intent and provisions. The bill's failure to advance beyond subcommittee referral highlights the importance of tracking legislative progress to assess policy impact. Future proposals would benefit from clear documentation to facilitate informed analysis and oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.